On February 20, 2026, PDS Biotechnology Corp announced an amendment to its Phase 3 clinical trial for PDS0101, adding progression-free survival as an interim endpoint to aid in accelerated approval for treating HPV16-positive head and neck cancer, while median overall survival remains the primary endpoint.